Rebamipide retards CCl₄-induced hepatic fibrosis in rats: Possible role for PGE₂

References

• Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M. 1998. Effects of rebami-pide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci. 43:160S–166S.
   Google Scholar
• Arakaki R, Eguchi H, Yamada A, Kudo Y, Iwasa A, Enkhmaa T. 2014. Anti-inflammatory effects of rebamipide eye drop administration on ocular lesions in a murine model of primary Sjögren’s syndrome. PLoS One. 9:e98390.
   PubMed Web of Science ®Google Scholar
• Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. 1998. Rebamipide: overview of mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 43: 5S–13S.
   PubMed Web of Science ®Google Scholar
• Bataller R. 2005. Liver fibrosis. J Clin Invest. 115:209–218.
   PubMed Web of Science ®Google Scholar
• Brenner DA. 2009. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc. 120:361–368.
   PubMedGoogle Scholar
• Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. 2001. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol. 41:661–690.
   PubMed Web of Science ®Google Scholar
• Choe JY, Park KY, Lee SJ, Park SH, Kim SK. 2010. Rebamipide inhibits TNFα-induced IL-8 expression by suppressing the NF-κB signal pathway in human umbilical vein endothelial cells. Inflamm Res. 59:1019–1026.
   PubMed Web of Science ®Google Scholar
• Cohen-Naftaly M, Friedman SL. 2011. Current status of novel anti-fibrotic therapies in patients with chronic liver disease. Ther Adv Gastroenterol. 4:391–417.
   PubMedGoogle Scholar
• de Minicis S, Brenner DA. 2007. NOX in liver fibrosis. Arch Biochem Biophys. 462:266–272.
   PubMed Web of Science ®Google Scholar
• Diao L, Mei Q, Xu JM, Liu XC, Hu J, Jin J, Yao Q, Chen ML. 2012. Rebamipide suppresses diclofenac-induced intestinal permeability via mitochondrial protection in mice. World J Gastroenterol. 18:1059–1066.
   PubMed Web of Science ®Google Scholar
• Dieter P, Scheibe R, Bezugla Y, Matthé E, Schuch S, Treffkorn L, Bernard B, Kamionka S, Kolada A. 2004. Regulatory role of prostaglandin E2 in liver (patho)-physiology is controlled at its site of synthesis and its action on the receptors. Comp Hepatol. 3:S35.
   Google Scholar
• Dieter P, Scheibe R, Télzer S, Kamionka S, Kolada A. 1999. Prostaglandin E2, an important regulator in (patho) physiological liver functions. In: Wisse E, Knook DL, de Zanger R, Arthur MJ, editors. Cells of the hepatic sinusoid. Leiden: Kupffer Cell Foundation. p. 6–10.
   Google Scholar
• Fischer R, Cariers A, Reinehr R, Haussinger D. 2002. Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology. 123:845–861.
   PubMed Web of Science ®Google Scholar
• Friedman SL. 2000. Molecular regulation of hepatic fibrosis: an integrated cellular response to tissue injury. J Biol Chem. 275:2247–2250.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Ishida W, Tanaka H, Harada Y, Fukushima A. 2014. Inhibition by reba-mipide of cytokine-induced or LPS-induced chemokine synthesis in human corneal fibroblasts. Br J Ophthalmol. 98:1751–1755.
   PubMed Web of Science ®Google Scholar
• Funahashi Y, Yoshida M, Yamamoto T, Majima T, Takai S, Gotoh M. 2014 Intra-vesical application of rebamipide suppresses bladder inflammation in a rat cystitis model. J Urol. 191:1147–1152.
   PubMed Web of Science ®Google Scholar
• Hahm KB, Lee KJ, Kim YS, Kim JH, Cho SW, Yim H, Joo HJ. 1998. Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide. Dig Dis Sci. 43:235–240.
   PubMed Web of Science ®Google Scholar
• Hahm KB, Park IS, Kim YS, Kim JH, Cho SW, Lee SI, Youn JK. 1997. Role of rebamipide on induction of heat-shock proteins and protection against reactive oxygen metabolite-mediated cell damage in cultured gastric mucosal cells. Free Radic Biol Med. 22:711–716.
   PubMed Web of Science ®Google Scholar
• Hong KW, Kim KE, Kim BY, Lee WS, Kim CD. 1998. Effect of rebamipide on liver damage and increased tumor necrosis factor in a rat model of endotoxin shock. Dig Dis Sci. 43:154S–159S.
   PubMed Web of Science ®Google Scholar
• Hui AY, Leung WK, Chan HL, Chan FK, Go MY, Chan KK, Tang BD, Chu ES, Sung JJ. 2006. Effect of celecoxib on experimental liver fibrosis in rat. Liver Int. 26:125–136.
   PubMed Web of Science ®Google Scholar
• Kim H, Seo JY, Kim KH. 2000. Inhibition of lipid peroxidation, NF-κB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci. 45:621–628.
   PubMed Web of Science ®Google Scholar
• Kinjo N, Kawanaka H, Akahoshi T, Yamaguchi S, Yoshida D, Anegawa G, Konishi K, Tomikawa M, Tanoue K, Tarnawski A, et al. 2008. Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications. Am J Physiol. 295:G1016–1024.
   PubMed Web of Science ®Google Scholar
• Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y. 2000. Rebamipide, an anti-ulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci. 45: 1608–1616.
   PubMed Web of Science ®Google Scholar
• Knolle P, Schlaak J, Uhrig A, Kempf P, Meyer zum Büschenfelde K, Gerken G. 1995. Human Kupffer cells secrete IL-10 in response to LPS challenge. J Hepatol. 22:226–229.
   PubMed Web of Science ®Google Scholar
• Kuzumoto Y, Sho M, Ikeda N, Hamada K, Mizuno T, Akashi S, Tsurui Y, Kashizuka H, Nomi T, Kubo A, et al. 2005. Significance and therapeutic potential of prostaglandin E2 receptor in hepatic ischemia/reperfusion injury in mice. Hepatology 42:608–617.
   PubMed Web of Science ®Google Scholar
• Li W, Zhao Y, Xu X, et al. 2015. Rebamipide suppresses TNFα-mediated inflammation in vitro and attenuates the severity of dermatitis in mice. FEBS J. 282:2317–2326.
   PubMed Web of Science ®Google Scholar
• Liu H, Wei W, Li X. 2009. Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum. Prostagland Lipid Mediat. 88:63–67.
   PubMed Web of Science ®Google Scholar
• Maher JJ. 2001. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis. 21:417–426.
   PubMed Web of Science ®Google Scholar
• Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman S, Safadi R. 2008. Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis. Hepatology 48:963–977.
   PubMed Web of Science ®Google Scholar
• Nishikimi M, Appaji N, Yagi K. 1972. The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem Biophys Res Commun. 46:849–854.
   PubMed Web of Science ®Google Scholar
• Otogawa K, Kinoshita K, Fujii H, Sakabe Ma, Shiga R, Nakatani K, Ikeda K, Nakajima Y, Ikura Y, Ueda M, et al. 2007. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steato-hepatitis: implications for pathogenesis of human non-alcoholic steato-hepatitis. Am J Pathol. 170:967–980.
   PubMed Web of Science ®Google Scholar
• Paik YH, Kim JK, Lee JI, Kang SH, Kim DY, An SH, Lee SJ, Lee DK, Han KH, Chon CY, et al. 2009. Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut 58:1517–1527.
   PubMed Web of Science ®Google Scholar
• Poli G. 2000. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Asp Med. 21:49–98.
   PubMedGoogle Scholar
• Ramachandran P, Iredale JP. 2012. Liver fibrosis: a bi-directional model of fibrogenesis and resolution. QJM. 105:813–817.
   PubMed Web of Science ®Google Scholar
• Reitman S, Frankel S. 1957. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 28:56–63.
   PubMed Web of Science ®Google Scholar
• Rincón-Sánchez AR, Covarrubias A, Rivas-Estilla AM, Pedraza-Chaverrí J, Cruz C, Islas-Carbajal MC, Panduro A, Estanes A, Armendáriz-Borunda J. 2005. PGE2 alleviates kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats with acute liver damage. Exp Toxicol Pathol. 56: 291–303.
   PubMed Web of Science ®Google Scholar
• Rosenbloom J, Mendoza FA, Jimenez SA. 2013. Strategies for anti-fibrotic therapies. Biochim Biophys Acta. 1832:1088–1103.
   PubMed Web of Science ®Google Scholar
• Sakurai K, Osaka T, Yamasaki K. 2005. Rebamipide reduces recurrence of experimental gastric ulcers: role of free radicals and neutrophils. Dig Dis Sci. 50:S90–S96.
   Google Scholar
• Sánchez-Valle V, Chávez-Tapia NC, Uribe M, Méndez-Sánchez N. 2012. Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr Med Chem. 19:4850–4860.
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Prati GM, Fasani P. 2006. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 43:1303–1310.
   PubMed Web of Science ®Google Scholar
• Satoh K. 1978. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta. 90:37–43.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Eisenburg J. 1975. Serum bilirubin determination in newborn infants. New micromethod. Fortschr Med. 93:1461–1466.
   PubMedGoogle Scholar
• Suetsugu H, Ishihara S, Moriyama N, Kazumori H, Adachi K, Fukuda R, Watanabe M, Kinoshita Y. 2000. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med. 136:50–57.
   PubMed Web of Science ®Google Scholar
• Tokuhara K, Hamada Y, Tanaka H, Yamada M, Ozaki T, Matsui K, Kamiyama Y, Nishizawa M, Ito S, Okumura T. 2008. Rebamipide, anti-gastric ulcer drug, up-regulates induction of iNOS in pro-inflammatory cytokine-stimulated hepatocytes. Nitric Oxide. 18:28–36.
   PubMed Web of Science ®Google Scholar
• Treffkorn L, Scheibe R, Maruyama T, Dieter P. 2004. PGE2 exerts its effect on the LPS-induced release of TNFα, ET-1, IL-1α, IL-6, and IL-10 via the EP2 and EP4 receptor in rat liver macrophages. Prostagland Lipid Mediat. 74:113–123.
   PubMed Web of Science ®Google Scholar
• Vassiliadis E, Larsen DV, Clausen RE, Veidal SS, Barascuk N, Larsen L, Simonsen H, Silvestre TS, Hansen C, Overgaard T, et al. 2011. Measurement of CO3-610, potential liver biomarker derived from MMP-9 degradation of collagen type III, in a rat model of reversible CCl4-induced fibrosis. Biomarker Insights. 6:49–58.
   PubMedGoogle Scholar
• Wang XZ, Zhang LJ, Li D, Huang YH, Chen ZX, Li B. 2003. Effects of transmitters and IL-10 on rat hepatic fibrosis induced by CCl4. World J Gastroenterol. 9:539–543.
   PubMed Web of Science ®Google Scholar
• Wen SL, Gao JH, Yang WJ, Lu YY, Tong H, Huang ZY, Liu ZX, Tang CW. 2014. Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes. J Gastroenterol Hepatol. 29:1932–1942.
   PubMed Web of Science ®Google Scholar
• Wynn TA, Barron L. 2010. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis. 30:245–257.
   PubMed Web of Science ®Google Scholar
• Yu J, Hui AY, Chu ES, Go MY, Cheung KF, Wu CW, Chan HL, Sung JJ. 2009. The anti–inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct–ligated rats. Liver Int. 29:25–36.
   PubMed Web of Science ®Google Scholar
• Zhang LJ, Chen YX, Chen ZX, Huang YH, Yu JP, Wang XZ. 2004. Effects of IL-10 and PDGF on expression of MMP-2 in rat and tissue inhibitor of metalloproteinase-1 in rat fibrotic liver and cultured hepatic stellate cells. World J Gastroenterol. 10:2574–2579.
   PubMed Web of Science ®Google Scholar
• Zhang LJ, Zheng WD, Chen YX, Huang YH, Chen ZX, Zhang SJ, Shi MN, Wang XZ. 2007. Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis. Hepato-gastroenterol. 54:2092–2098.
   PubMed Web of Science ®Google Scholar